Indeed, osteosarcoma cells are known to express a number of surface proteins that might be of therapeutic relevance, including B7-H3, GD2 and HER2, which can be targeted using antibody–drug conjugates or adoptive cell therapies [31–33]. This evidence concerns the gene ERBB2 and osteosarcoma.